Lasa Supergenerics share news and announcements
NSE: LASABSE: 540702Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 19 Oct 2026. Previous close ₹5.16.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹25 Cr3,595th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 0.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Sep 2026
- −24.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Sep 2026
- −24.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day.
- 37,588
Lasa Supergenerics share news and announcements
825 announcements, routine notices left out, newest first. Page 7 of 17.
Apr 2022
25 Apr · Related Party Transaction
25 Apr · Disclosure Of Related Party Transaction Under Regulation 23(9) Of SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015.
12 Apr · Compliances - YEARLY CERTIFICATE FROM PRACTICING COMPANY SECRETARY UNDER REG 40(9) OF SEBI (LODR) REGULATIONS 2015.
12 Apr · General updates
8 Apr · Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 07 Apr · Legal
The exchange asked on 6 Apr 2022
6 Apr · LASA : Significant movement in price has been observed in Lasa Supergenerics Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Price movement6 Apr · Legal
Exchange has sought clarification from Lasa Supergenerics Ltd on April 6, 2022 with reference to significant movement in price, in order to ensure that investors have latest relevant ....5 Apr · Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 For Period Ended March 31, 2022
Mar 2022
Feb 2022
7 Feb · Board meeting
Jan 2022
21 Jan · Shareholding for the Period Ended December 31, 2021
Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click ....12 Jan · Intimation Of Filing Of An Application Before The National Company Law Tribunal Under Section 7 Of Insolvency And Bankruptcy Code, 2016 ('IBC')
7 Jan · Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Dec 2021
27 Dec · Analysts
10 Dec · Disclosure
Nov 2021
29 Nov · Compliance Under Regulation 23(9) Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
17 Nov · Management
17 Nov · Management